Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Investor Presentation (July 2025)
18 slides from Island Pharmaceuticals's investor presentation, Jul 9, 2025
Slide 1: Combatting Urgent Viral Disease Threats
For personal use only COMBATTING URGENT VIRAL DISEASE THREATS DR DAVID FOSTER, MANAGING DIRECTOR July 2025 (ASX: ILA) ISLAND PHARMACEUTICALS 1 July 2025
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Island Pharmaceuticals Limited (ABN 641 183 842) (Company or Future performance Island Pharmaceuticals). This presentation contains certain "forward-looking statements". The words "expect", "anticipate", Not an offer or financia
Slide 3: For personal use only
For personal use only Galidesivir acquisition executed Major market - expedited approval potential Island Pharmaceuticals route defined (ASX: ILA) is an antiviral therapeutics company Positive results in Phase 2a/b PROTECT clinical trial in dengue targeting infectious diseases aggressive models comp
Slide 4: Corporate Overview
CORPORATE OVERVIEW Snapshot Price & volume (12 month) For personal use only Shares on issue1: 236,093,034 Price per share1: $0.145 Market capitalisation1: $34.24m Cash at bank (31 March 2024)2: $4.82m May 2025 capital raise: $3.6m DoD grant funding to directly support US$625k the Phase 2a/b PROTECT
Slide 5: Benefits of Drug Repurposing
BENEFITS OF DRUG REPURPOSING For personal use only ILA is well advanced in its clinical development pipeline ISLAND PHARMACEUTICALS 5 July 2025
Slide 6: Galidesivir Acquisition Transaction
GALIDESIVIR ACQUISITION TRANSACTION For personal use only • Asset acquisition of galidesivir and related compounds • Clinical program and robust pre-clinical data package • International IP portfolio • Favourable terms: • Upfront $550,000 USD including $50,000 option fee • US$500,000 upon completion
Slide 7: Galidesivir Program
GALIDESIVIR PROGRAM For personal use only Program was developed in collaboration with NIAID (>US$70m in funding to date) to prepare for and respond to high priority virus threats and emerging viral infections • Asset purchase agreement executed with NASDAQ-listed, BioCryst Pharmacueticals Inc. (Nasd
Slide 8: Galidesivir Program Summary
For personal use only GALIDESIVIR PROGRAM SUMMARY ISLAND PHARMACEUTICALS 8 July 2025
Slide 9: Galidesivir Unlocks Another Major Market
GALIDESIVIR UNLOCKS ANOTHER MAJOR MARKET For personal use only • Demonstrated activity against 20+ viruses – many with no available treatment • Activity against potential bioterror threats • Potential markets: • Government stockpile programs • Numerous antiviral programs • Ripe potential for partner
Slide 10: Broad Spectrum Activity Demonstrated
BROAD SPECTRUM ACTIVITY DEMONSTRATED For personal use only Data highlights activity in vitro against multiple RNA viruses from diverse families Virus Family Virus Strain/Variant Virus Family Virus Strain/Variant Marburg Musoke Nipah virus Malaysia Paramyxo HRS A2 Marburg Ci67 Filoviridae Measles Chi
Slide 11: Multiple Phase Human Safety Clinical Studies
MULTIPLE PHASE 1 HUMAN SAFETY CLINICAL STUDIES For personal use only SAD Phase1 HV – SAD / MAD IM Study 101 Highest Dose: 10 mg/kg MAD Highest Dose: 10 mg/kg 7 Completed days Cohort 1: 5 mg/kg Phase1 HV – SAD IV Study 106 Cohort 2: 10 mg/kg Cohort 3: 15 mg/kg Completed Cohort 4: 20 mg/kg Phase 1
Slide 12: Demonstrated In Vivo Antiviral Effects
DEMONSTRATED IN VIVO ANTIVIRAL EFFECTS For personal use only Impact achieved with delayed dosing across a broad range of viruses Animal Species Virus Dose Regimen Key Results Hamsters Yellow Fever 100 mg/kg BID 7 days 100% survival initial dose 3dpi, 80% survival initial dose 4dpia; 12.5% survival c
Slide 13: Efficacy in NHPs Infected with MARV
EFFICACY IN NHPS INFECTED WITH MARV For personal use only Figure a: survival Animals (n=6/group) were challenged with MARV by SC injection, and Galidesivir (15mg/kg BID) or vehicle was administered IM beginning 1 hr (RED) 24 hr (BLUE) or 48 hr (GREEN) after challenge. Vehicle control (WHITE). *P<0.0
Slide 14: Suppression of Marburg Virus Proliferation in Infected NHPs
SUPPRESSION OF MARBURG VIRUS PROLIFERATION IN INFECTED NHPS For personal use only Figure b: viral load Serum viral RNA load was determined in animals (n=6 per group) treated IM beginning 1 hr (RED) 24 hr (BLUE) or 48 hr (GREEN) after challenge. Vehicle control (WHITE). *P<0.05 for comparison of trea
Slide 15: Potential Regulatory Path
POTENTIAL REGULATORY PATH 4-8 years 4-6 years 1 year For personal use only In vivo Experiment experiments Phase 1 Phase 2 Phase 3 Basic Study Drug Design NDA in vitro (animal Clinical Trials Clinical Trials Clinical Trials studies) In vivo N Basic Study Drug Design Experiment in vitro experiments (2
Slide 16: Immediate Next Steps
IMMEDIATE NEXT STEPS For personal use only Island focused on a near term program to unlock value • Completion of all asset transfer from BioCryst to Island • Finalise enquiries with US FDA • Consult US FDA regarding potential for Animal Rule inclusion • Ongoing review of data package • Preparations
Slide 17: Island Pharmaceuticals
For personal use only Island Pharmaceuticals (ASX: ILA) islandpharmaceuticals.com @IslandPharma Island Pharmaceuticals ISLAND PHARMACEUTICALS 17 July 2025
Slide 18: Appendix 1: Sources
APPENDIX 1: SOURCES For personal use only Slide 12: a Julander J. G et al. BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model. Antimicrob Agents Chemother 2014;58(11):6607—14 b Whitney, J. B. et al. Galidesivir, a direct-acting antiviral, abrogates viremia in rhes
Island Pharmaceuticals — Investor Presentation (July 2025) on 6ix